Damora Therapeutics
GLTO | NASDAQ
$21.58
-$0.75 (-3.36%)
At close: Jun 4, 2026, 12:02 PM ET
Damora Therapeutics Company Profile
Company profile explainedCompany Profile
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.
Key Executives
| Name | Position |
|---|---|
| Hans T. Schambye | Co-Founder, President, Chief Executive Officer & Director |
| Lori C. Firmani | Chief Financial Officer |
| Becker Hewes | Chief Medical Officer |
| Garrett Winslow | Senior Vice President, General Counsel & Corporate Secretary |
| Hakon Leffler | Co-Founder |
| Matthew Kronmiller | EVice President of Strategy & Chief Business Officer |
| Sherwin Sattarzadeh | Interim Principal Executive Officer & COO |
| Tariq Sethi FRCP | Co-Founder |
| Ulf J. Nilsson | Co-Founder |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 28, 2026 | 4 | Filing |
| Aug 13, 2026 | 4 | Filing |
| Aug 13, 2026 | 3 | Filing |
| Aug 12, 2026 | EFFECT | Filing |
| Aug 10, 2026 | S-8 POS | Filing |
| Aug 10, 2026 | S-8 POS | Filing |
| Aug 10, 2026 | POSASR | Filing |
| Aug 10, 2026 | S-8 POS | Filing |
| Aug 10, 2026 | S-8 POS | Filing |
| Aug 10, 2026 | S-8 POS | Filing |
Damora Therapeutics
| Country | United States |
| IPO Date | Oct 28, 2020 |
| Industry | Medical - Pharmaceuticals |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Jennifer A. Jarrett |
Contact Details
Building 23 Boston,
Massachusetts 02453 United States
Stock Details
| Ticker Symbol | GLTO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001800315 |
| CUSIP Number | 36322Q206 |
| ISIN Number | US36322Q2066 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove GLTO